

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE DECEMBER 9, 2021 MEETING**

DUR Board Roster: State Fiscal Year 2022 (July 1, 2021 – June 30, 2022)	Mar 2021	Jun 2021	Sep 2021	Dec 2021
Lauren Bloodworth, PharmD	✓	✓	✓	✓
Terrence Brown, PharmD	✓		✓	✓
Patrick Bynum, MD	✓	✓	✓	✓
Cesar Cardenas, MD	NA	NA	NA	✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	✓		✓	
Ray Montalvo, MD		✓	✓	✓
Holly Moore, PharmD	✓		✓	
Joshua Pierce, PharmD	NA	NA	NA	✓
Cheryl Sudduth, RPh		✓		
James Taylor, PharmD (Chair)	✓		✓	
Alan Torrey, MD		✓		
TOTAL PRESENT**	9	7	9	7

*** Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPh, CPM, Pharmacy Director; Dennis Smith, RPh, DUR Coordinator; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Sue Reno, RN, Program Integrity;

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, Research Assistant Professor;

Change Healthcare Staff:

Paige Clayton, PharmD, On-Site Clinical Pharmacist;

Coordinated Care Organization (CCO) Staff:

Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare;

Alliant Health Staff:

Buddy Ogletree, PharmD, Clinical Pharmacist;

Visitors:

Keanna Dandridge, Norvartis; Brian Hall, BMS; David Large, Biohaven; Chrystal Mayes, Sanofi Genzyme; Harper Mims, Capitol Resources; Michelle Peoples, Lilly; Cathy Prine-Eagle, Merck; Lisa Tracz, Global Blood Therapeutics; Shauna Williams, Bayer; Julie Young, Abbvie; Paula Whatley, Novo Nordisk.

Call to Order/Welcome:

Ms. Dunaway called the meeting to order at 1:05 pm. Mr. Dennis Smith welcomed everyone to our first live meeting in 2 years. DOM staff and Board members took a few moments for introductions.

OLD BUSINESS:

Dr. Bloodworth moved to approve the minutes from the September 2021 DUR Board Meeting, seconded by Dr. Brown, and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman presented the resource utilization report for September 2021. Enrollment numbers continued to climb. The number of beneficiaries with pharmacy benefits was up 10% compared to September 2020 and the number of prescription fills also increased 19.4% compared to September 2020. Dr. Pittman discussed several trends and items of note from the resource report.

NEW BUSINESS:**Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred September 2021 – November 2021.

Special Analysis Projects:**Statin Therapy for Patients with Diabetes**

MS-DUR presented a report detailing performance on the Health Effectiveness Data and Information Set (HEDIS) Statin Therapy for Patients with Diabetes (SPD) quality measure among Medicaid beneficiaries for calendar year (CY) 2020. The HEDIS-SPD measure reports the percentage of members 40-75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD). Two rates are reported:

1. Received a Statin Therapy. Members who were dispensed at least one statin medication of any intensity during the measurement year.
2. Statin Adherence 80%. Members who remained on a statin medication of any intensity for at least 80% of the treatment period.

It was noted that while the overall rates for both measures were the same (45.8%), performance was different across pharmacy plans. Beneficiaries enrolled in the coordinated care organizations (CCOs) had higher rates for 'Received Statin Therapy' compared to FFS. The

rates for 'Statin Adherence' varied across plans with Magnolia having the highest. It was noted that each of the CCOs have 'Gaps in Care' programs addressing the utilization of statins among individuals with diabetes.

The following recommendations were presented:

1. MS-DUR should work with DOM to develop and implement a 'Gaps In Care' program for the FFS population aimed at improving the rate of beneficiaries with diabetes prescribed statin therapy.
2. DOM should work with CCOs and FFS programs to develop plans for improving adherence rates for beneficiaries with diabetes prescribed statin therapy.

Following discussion, Dr. Montalvo made a motion, seconded by Dr. Bloodworth, and unanimously approved by the Board to accept the recommendations presented.

Asthma Guideline Update and UPDL Implications

At the March 2019 DUR Board Meeting, an overview of asthma, along with performance on related quality measures, was presented. The board recommended MS-DUR design and implement an educational intervention program to educate providers about performance on asthma quality measures. Prior to implementing any provider education, an updated report from the Global Initiative for Asthma (GINA) was released in April 2019 and recommended significant changes in asthma management. The landmark changes involved the recommendation that all adults and adolescents with asthma receive symptom-driven or regular low-dose inhaled corticosteroid (ICS) containing controller treatment, specifically low-dose ICS-formoterol. The Division of Medicaid (DOM) requested MS-DUR conduct an updated analysis and review the Universal Preferred Drug List (UPDL) for any issues that may limit providers from prescribing in accordance with the updated guidelines

MS-DUR presented a report on performance on the Asthma Medication Ratio (AMR) quality measure, healthcare utilization costs associated with asthma, and potential UPDL issues that may limit providers from prescribing in accordance with the updated guidelines.

The following recommendations were presented:

1. The UPDL quantity limit for Symbicort® should be updated to allow for its prescribing in both as-needed and maintenance therapy concurrently.
2. MS-DUR should design and implement an educational intervention program to educate providers on the updated asthma guidelines, performance on asthma medication management quality measures, and any asthma-related UPDL updates.

At the conclusion of discussions by the Board, Dr. Montalvo made a motion, seconded by Dr. Brown, and unanimously approved by the Board to accept the recommendations presented.

90-Day Drug List Utilization

MS-DUR presented a report detailing the utilization of medications included on Medicaid's 90-Day Drug List. This list may be used by prescribers as a tool to manage a beneficiary's

prescription drug limit, unless clinically contraindicated. Dr. Pittman presented utilization trends by number of prescription fills, proportion of fills for that specific drug class, and dollars paid. This report for the DUR Board was for informational purposes only.

No action was sought as a result of this report.

FDA Drug Safety Updates:

Dr. Pittman presented FDA drug safety communications for September 2021 – November 2021.

Pharmacy Program Update:

Ms. Kirby provided a pharmacy program update highlighting the following updates:

- 1) Medicaid will be changing their fiscal agent from Conduent to Gainwell. A tentative 'go live' date is proposed for July 2022. Providers should begin seeing communications related to that change soon.
- 2) DOM is continuing to make updates to COVID-19 billing guidance.
- 3) Pharmacy permits are expiring at the end of December 2021. Renewals need to be submitted before January 1, 2022 to DOM to prevent any interruptions in reimbursements.
- 4) The UPDL changes will go into effect January 1, 2022.

Next Meeting Information:

The following proposed 2022 meeting dates were presented to the Board: March 3, 2022; June 9, 2022; September 15, 2022; and December 8, 2022.

Dr. Bloodworth motioned to adjourn the meeting at 2:07 pm, seconded by Dr. Montalvo, and unanimously approved by the Board.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Search Login




Mississippi Public Meeting Notices

ADVANCED NOTICE SEARCH

SEARCH RESULTS

Notices: 2 notices found.

Notice	Date	Status	Public Body	Agency	Attachments
Drug Utilization Review Board Meeting	12/9/2021 1:00:00 PM	Published	Division of Medicaid	Division of Medicaid	DFA Meeting notification DUR 2021.docx Added 1/14/2021

Meeting Location: Meetings will be held virtually until further notice. Please visit [Medicaid.ms.gov](https://www.Medicaid.ms.gov) and click on the Pharmacy Information link for further information.

Contact Information: Office of Pharmacy:
Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: March 4, 2021; June 10, 2021; September 16, 2021; and December 9, 2021 at 1PM

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.